口服补液盐对呼吸道感染发热患者的辅助治疗价值

Efficacy of oral rehydration salts on soldiers with fever from respiratory tract infection

目的:探讨口服补液盐对部队官兵呼吸道感染发热患者的辅助治疗价值.方法:选取明确诊断为急性扁桃体炎和细菌性肺炎的部队官兵发热患者60例,随机分为对照组和治疗组各30例.对照组采取常规的抗感染、退热等对症治疗,治疗组在对照组的治疗基础上给予口服补液盐辅助治疗.分析比较两组患者退热时间、住院天数、治疗前后伴随全身症状评分(精神萎靡、食欲不振、睡眠障碍、四肢无力)及不良反应等指标的差异.结果:治疗组退热时间(2.2±0.7)d,对照组为(3.9±2.2)d,组间有统计学差异(t=4.81,P<0.05);治疗组住院天数(6.4±1.9)d,对照组为(8.5±2.7)d,组间有统计学差异(t=6.07,P<0.05);治疗组治疗后全身症状评分为(4.56±2.29)分,对照组为(9.27±3.21)分,组间有统计学差异(t′=13.87,P<0.05).结论:辅助使用口服补液盐能够缩短呼吸道感染发热患者的退热时间及住院天数,可显著改善精神萎靡、食欲不振和四肢无力等全身症状,提高患者发热期间生活质量.

Objective:To investigate the efficacy of oral rehydration salts on soldiers with fever from respiratory tract infection.Methods:Totally 60 soldiers with fever from respiratory tract infection(bacterial pneumonia or acute tonsilitis)were randomly divided into the trial group(n=30)and the control group(n=30).The control group received routine anti infection treatment,while the trial group administered oral rehydration salt besides routine anti infection treatment.After treatment,the two groups were compared regarding average defervescence time,hospital stay,the score of general symptoms(such as spiritlessness,loss of appetite,poor sleep and daytime tiredness)and incidence of adverse reaction.Results:The average defervescence time in the trial group[(2.2±0.7)days]was significantly shorter than that in the control group[(3.9±2.2)days](t=4.81,P<0.05).The hospital stay in the the trial group was(6.4±1.9)days,shorter than that in the control group,which was(8.5±2.7)days(t=6.07,P<0.05).The score of general symptoms were(4.56±2.29)in the trial group and(9.27±3.21)in the control group,and the difference was of statistical significance(t'=13.87,P<0.05).Conclusion:Oral rehydration salts could effectively shorten the average defervescence time and hospital stay of soldiers with fever from respiratory tract infection,relieve general symptoms(such as spiritlessness,loss of appetite,poor sleep and daytime tiredness)and improve their life quality remarkably during the fever.